![Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant | Communications Medicine Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant | Communications Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs43856-022-00141-4/MediaObjects/43856_2022_141_Fig1_HTML.png)
Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS-CoV-2 Omicron variant | Communications Medicine
![Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies - eBioMedicine Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies - eBioMedicine](https://www.thelancet.com/cms/asset/dd1d2ce4-5ebe-4811-a76c-1615a5e47ad7/gr1.jpg)
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies - eBioMedicine
![COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7104e2_IncidenceDeathRatesOmicron_IMAGE_21Jan22_1200x627.jpg?_=64029)
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 | MMWR
![ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/news/2022/09/atagi-statement-on-use-of-the-moderna-bivalent-original-omicron-vaccine.png?itok=BIYw_3RB)
ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/91d19b8e-2f0b-4e13-8d9b-69e012d37e25/gr1.jpg)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Quarta dose contro Covid-19: perché, a chi, quando e con quale vaccino - Network Bibliotecario Sanitario Toscano Quarta dose contro Covid-19: perché, a chi, quando e con quale vaccino - Network Bibliotecario Sanitario Toscano](https://www.mdpi.com/vaccines/vaccines-10-01924/article_deploy/html/images/vaccines-10-01924-g001.png)
Quarta dose contro Covid-19: perché, a chi, quando e con quale vaccino - Network Bibliotecario Sanitario Toscano
![Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01705-6/MediaObjects/41591_2022_1705_Fig1_HTML.png)